bpc-157 peptide human clinical trials safety BPC-157: What the Science Says (Zero Trials) bpc-157 human clinical trials evidence

The process begins with a detailed medical history to determine if the itching is related to an underlying condition such as kidney disease, liver disease, or thyroid problems

None of this changes the bottom line: no completed human clinical trial exists for any BPC-157 indication

As most undesirable effects are based on post-marketing spontaneous reporting, frequency estimation is not possible. Immune system disorders Frequency not known: Hypersensitivity reactions, such as sweating, tachycardia, and skin reactions with itching and urticaria. Gastrointestinal disorders Less frequent: Gastrointestinal complaints, such as nausea, vomiting, diarrhoea and abdominal pain. Skin and subcutaneous tissue disorders Less frequent: Cases of acne or eczema have been reported after high doses of Vitamin B12. General disorders and administration site conditions Frequency not known: Injection site reactions. Renal and urinary disorders Less frequent: Chromaturia (reddish urine, appeared during the first 8 hours after an administration and typically resolves within 48 hours).Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the 6.04 Adverse Drug Reactions Reporting Form, found online under SAHPRAs publications

Are there clues that help explain your symptoms